Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an
important tool for rational drug development and drug use, where developed models …

Because of increasing antimicrobial resistance and the shortage of new antibiotics, there is
a growing need to optimize the use of old and new antibiotics. Modelling of the …

This article represents the first in a series of tutorials on model evaluation in nonlinear mixed
effect models (NLMEMs), from the International Society of Pharmacometrics (ISoP) Model …

Background The sites of mycobacterial infection in the lungs of tuberculosis (TB) patients
have complex structures and poor vascularization, which obstructs drug distribution to these …

This document was developed to enable greater consistency in the practice, application,
and documentation of Model‐Informed Drug Discovery and Development (MID3) across the …

Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …

The value of in silico methods in drug development and evaluation has been demonstrated
repeatedly and convincingly. While their benefits are now unanimously recognized …

Population pharmacodynamic (PD) models describe the time course of drug effects, relating
exposure to response, and providing a more robust understanding of drug action than single …

Circulating cell-free DNA is considered as one of the major breakthroughs in the field of
innovative diagnosis, used as a liquid biopsy. The kinetic parameters of a biomarker are …

Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic
(PK) modelling approaches are widely accepted in non-radiopharmaceutical drug …